Folate-conjugated nanovehicles: Strategies for cancer therapy

Mater Sci Eng C Mater Biol Appl. 2020 Feb:107:110341. doi: 10.1016/j.msec.2019.110341. Epub 2019 Oct 23.

Abstract

Cancer theranostics represents a strategy that aims at combining diagnosis with therapy through the simultaneous imaging and targeted delivery of therapeutics to cancer cells. Recently, the folate receptor alpha has emerged as an attractive theranostic target due to its overexpression in multiple solid tumors and its great functional versatility. In fact, it can be incorporated into folate-conjugated nano-systems for imaging and drug delivery. Hence, it can be used along the line of personalized clinical strategies as both an imaging tool and a delivery method ensuring the selective transport of treatments to tumor cells, thus highlighting its theranostic qualities. In this review, we will explore these theranostic characteristics in detail and assess their clinical potential. We will also discuss the technological advances that have allowed the design of sophisticated folate-based nanocarriers harboring various chemical properties and suited for the transport of various therapeutic agents.

Keywords: Cancer therapy; Folate receptor; Nanoparticles; Targeted delivery.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacology
  • Dendrimers / chemistry
  • Dendrimers / pharmacology
  • Drug Delivery Systems / methods*
  • Folate Receptor 1 / metabolism
  • Folic Acid / chemistry*
  • Folic Acid / metabolism
  • Folic Acid / pharmacokinetics
  • Humans
  • Liposomes / administration & dosage
  • Molecular Targeted Therapy / methods
  • Nanostructures / administration & dosage*
  • Nanostructures / chemistry
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents
  • Dendrimers
  • Folate Receptor 1
  • Liposomes
  • Folic Acid